Cell Immunotherapy Sector Falls 0.08%; Hengrui Leads RMB1.82 Billion Capital Outflow
The cell immunotherapy concept sector fell 0.08% at the close on August 12, with main capital posting a net outflow of RMB1.82 billion. Hengrui Pharmaceuticals led the outflows at RMB289 million, followed by Hanyu Pharmaceutical (RMB241 million), Rongchang Bio (RMB201 million) and Bioptes (RMB130 million). Six of 45 net-outflow stocks exceeded RMB100 million. Meanwhile, 26 sector stocks advanced, led by Baihua Pharmaceutical (10.04%), David Medical (4.86%) and Nanhua Bio (4.05%). Bright Pharmaceutical recorded the largest net inflow at RMB44.6 million.
At the close of trading on August 12, the cell immunotherapy concept sector fell 0.08%, ranking among the top decliners in the concept sector list. Within the sector, Chengda Pharmaceutical, Jinan Biotech and Kingmed Diagnostics led the declines, while 26 stocks rose, led by Baihua Pharmaceutical, David Medical and Nanhua Bio, which gained 10.04%, 4.86% and 4.05%, respectively.
The sector recorded a net outflow of RMB1.82 billion in main capital during the session, with 45 stocks posting net outflows and six exceeding RMB100 million each. Hengrui Pharmaceuticals led the outflows at RMB289 million, followed by Hanyu Pharmaceutical at RMB241 million, Rongchang Bio at RMB201 million and Bioptes at RMB130 million. The top net inflows were Bright Pharmaceutical (RMB44.6 million), International Medicine (RMB13.73 million) and Hainan Haiyao (RMB7.91 million).